Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

578 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens AB, Leiser A, Mayer T, Chan N, Spencer K, Girda E, Malhotra J, Chan T, Subbiah V, Groisberg R. Palmeri M, et al. Among authors: subbiah v. ESMO Open. 2022 Feb;7(1):100336. doi: 10.1016/j.esmoop.2021.100336. Epub 2021 Dec 23. ESMO Open. 2022. PMID: 34953399 Free PMC article.
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Groisberg R, et al. Among authors: subbiah v. Oncotarget. 2017 Jun 13;8(24):39254-39267. doi: 10.18632/oncotarget.16845. Oncotarget. 2017. PMID: 28424409 Free PMC article.
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Dembla V, et al. Among authors: subbiah v. Sci Rep. 2017 Nov 21;7(1):15963. doi: 10.1038/s41598-017-13114-8. Sci Rep. 2017. PMID: 29162825 Free PMC article.
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
Groisberg R, Hong DS, Roszik J, Janku F, Tsimberidou AM, Javle M, Meric-Bernstam F, Subbiah V. Groisberg R, et al. Among authors: subbiah v. Mol Cancer Ther. 2018 Jul;17(7):1595-1601. doi: 10.1158/1535-7163.MCT-17-1107. Epub 2018 Apr 13. Mol Cancer Ther. 2018. PMID: 29654067 Free PMC article.
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Maymani H, et al. Among authors: subbiah v. Lung Cancer. 2018 Jun;120:137-141. doi: 10.1016/j.lungcan.2018.03.020. Epub 2018 Apr 11. Lung Cancer. 2018. PMID: 29748008 Free PMC article.
Of mice and men: lost in translation.
Groisberg R, Maitra A, Subbiah V. Groisberg R, et al. Among authors: subbiah v. Ann Oncol. 2019 Apr 1;30(4):499-500. doi: 10.1093/annonc/mdz041. Ann Oncol. 2019. PMID: 30715159 Free PMC article. No abstract available.
578 results